News

A recent study found that sepsis, genetic mutations and perinatal asphyxia are common causes of severe neonatal thrombocytopenia in China.

A recent study found a link between key DNA markers and type I CD36 deficiency in platelet donors to patients with FNAIT.

Researchers of a recently published review stated more data is needed to confirm the link between ITP and the risk of FNAIT.

A recent study found more data is needed to confirm the link between HPA antigens and the development of autoimmune thrombocytopenia.

A recent study found no significant differences in accuracy between methods for detecting detecting anti-HPA antibodies responsible for FNAIT.

An investigational drug developed by Rallybio to prevent FNAIT produced positive results in a phase 1 clinical trial.

A recent analysis highlighted the need for additional data on the causes and mechanisms of platelet transfusion refractoriness.

Neonatal fragment crystallizable receptor (FcRn) inhibitors could significantly decrease complications associated with FNAIT, recent studies show.

Results from the phase 1 clinical trial of RLYB212, an experimental therapy intended for FNAIT prevention, were recently published.

A new study to compare treatment with nipocalimab versus IVIG in pregnant people at risk of FNAIT will be enrolling patients soon.